TNGX Q1 2025 Earnings — Tango Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TNGXTango Therapeutics, Inc.

$2B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M-16.7% YoY

Gross Profit

$5M100.0% margin

Operating Income

-$43M-788.8% margin

Net Income

-$40M-739.5% margin

EPS (Diluted)

$-0.36

QoQ Revenue Growth

+31.0%

Cash Flow

Operating Cash Flow

-$42M

Free Cash Flow

-$42M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$274M

Total Liabilities

$108M

Stockholders' Equity

$167M

Cash & Equivalents

$58M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$6M	-16.7%
Gross Profit	$5M	$6M	-16.7%
Operating Income	-$43M	-$42M	-0.7%
Net Income	-$40M	-$38M	-5.2%

Revenue Segments

Collaboration Revenue

$5M100%